Cancer is the leading cause of death worldwide. Clinically, chemotherapy plays a vital role in combating cancer, followed by surgery and radiotherapy. Chemotherapy involves the utilization of chemotherapeutic or cytotoxic agents, which are primarily employed to inhibit or control the rate of growth of tumor tissues. Despite, the availability of potent anti-cancer drugs in the clinic, by large, the use of these cytotoxic agents impose some limitations, such as:

• The non-specific distribution at the tumour site, which results in the insufficient penetration of such drugs into the tumour tissues ,

• The non-selective action of these agents results in the damage to the normal healthy cells, causing extreme side effects to the body and further limits the dose or its frequency of dosing,
• The development of multi-drug resistance (MDR).
  All these cases reduce the efficacy of chemotherapeutic compounds.
  RNAi-based therapy is a promising therapeutic approach based on the 2006 Nobel Prize winning research of Andrew Fire and Craig C. Mello which uncovered the basic properties of RNA interference in the nematode worm. The RNA interference (RNAi) technology has emerged as one of the most promising strategies for cancer therapeutics, primarily due to its high specificity, precise mechanism of action and potency.
  The basic idea behind RNAi is simple: a short sequence
  of double stranded RNA (dsRNA) could enter the cell,
  and separate into single-strand siRNA molecules which
  then target and bind a specific messenger RNA. Specific
  intracellular mechanisms (known as RISC) identify the
  construct and degrade it; thereby reducing expression
  of a target protein. The strategy is also advantageous
  in terms of its capability to target multiple oncogenes
  simultaneously. In addition to this, the RNAi technology
  aids to improve the efficacy of chemotherapeutic agents
  by overcoming the multi-drug resistant (MDR) effects.
  RNAi-based therapeutics remains one of the most
  promising strategies for the effective cancer treatment
  due to its high target-specificity, precise mechanism
  of action, greater potency and reduced side effects.
  Although tremendous progress and advances have been made in the past few years to develop nanotechnology- based efficient non-viral delivery systems, there are still many hurdles and challenges that must be conquered to achieve the target of clinically relevant formulation in terms of safety, specificity and efficacy.
  Despite some major advances in this field of therapeutics, there are, however, some challenges that needs to be overcome, such as the biological safety, serum stability, off-target effects and effective in vivo delivery. Polymer 9000 Universal, our core technology and product, has been invented to face those challenges. Polymer 9000 Universal, like no other solution, is being sought for safe and effective delivery of stable siRNA molecules.